Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.781 USD | +2.76% | +20.33% | -46.09% |
Apr. 09 | Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT | CI |
Apr. 08 | Declaration of Voting Results by Seres Therapeutics | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.09% | 115M | |
-0.35% | 105B | |
+4.00% | 97.5B | |
+2.45% | 22.19B | |
-15.96% | 21.33B | |
-7.63% | 18.68B | |
-41.41% | 16.6B | |
-19.03% | 14.52B | |
+7.82% | 14.09B | |
+22.53% | 10.99B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Seres Therapeutics : Publishes Positive Data on Phase 1b Ulcerative Colitis Study